Market Segmentation

• Products (Consumables, Instruments, Software)
• Mechanism (DNA Methylation, Histone Modification, RNA Modification, and Others)
• Application (Oncology, Cardiovascular Diseases, Immunology, Metabolic Diseases, and Others)
• Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Other Technologies (MS, Flow Cytometry))
• End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), and Other End Users)

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, India, Japan, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Epigenetics Inclined by Rising Prevalence of Cancer
• Strategic Initiatives by Key Market Players
• Increasing Government Initiatives in the Field of Epigenetics

Market Challenges

• High Cost of Instruments
• Dearth of Skilled Professionals in Epigenetic Research

Market Opportunities

• Technological Advancement Toward Innovation in Epigenetics
• Expanding Epigenetic Applications in Non-Oncology Diseases

Key Companies Profiled

Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer Inc., Exact Sciences Corporation, Merck KGaA, MDxHealth, Agilent Technologies, Inc., Abcam Plc, Pacific Biosciences of California, Inc., Zymo Research Corporation, Active Motif, Inc., Promega Corporation

Key Questions Answered in this Report:

• How is epigenetics revolutionizing oncology research and clinical diagnostics?
• What are the major market drivers, challenges, and opportunities in the global epigenetics market?
• What are the underlying structures resulting in the emerging trends within the global epigenetics market?
• How is the COVID-19 pandemic impacting the global epigenetics ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of epigenetics targeted therapies?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments?
• What are the growth opportunities for the epigenetics companies in the region of their operation?
• Who are the leading players with significant offerings in the global epigenetics market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

The growth of the epigenetics market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing, and the advancement of the products. However, there are significant challenges restraining the market growth, such as the high-cost epigenetics instruments and dearth of skilled professionals in epigenetic research.

Epigenetic mechanisms are being linked to a growing number of chronic diseases and disorders, including cardiovascular diseases, autoimmune diseases, and neurodegenerative disorders, as well as environmental cues and nutrition, which have a significant impact on epigenetic processes such as DNA methylation, histone modification, and non-coding RNA.

Healthcare experts have found the epigenetics market to be one of the highest booming markets, and the global market is predicted to grow at a CAGR of 17.11% during the forecast period 2021-2031.

The epigenetics market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Epigenetic alterations can be maintained from cell to cell as cells divide and can be inherited through the generations.

Moreover, epigenetic changes are required for normal development and health, and they can also be responsible for some disease states. Disturbing any of the three marks that contribute to epigenetic modification can cause abnormal activation or silencing of genes. In addition, the market of epigenetics is rising due to technological advancements in products offered by the companies.

Competitive Landscape

The growth of this market can be majorly attributed to the presence of well-established guidelines regarding epigenetics, presence of established companies undertaking key business strategies, rising number of cancer cases, and increasing adoption of products based on advanced molecular technologies by the pharmaceutical and biotechnological companies, among others.

Further, increasing focus on research pertaining to the epigenetics biomarkers such as DNA, histones, and non-coding RNA is also expected to support the growth of the epigenetics market during the forecast period, 2021-2031.

The growth of other technologies, such as next-generation sequencing and whole genome sequencing, can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders.

Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

The post Epigenetics Market – A Global and Regional Analysis: Focus on Product, Mechanism, Technology, Application, End User, and Region – Analysis and Forecast, 2021-2031 first appeared on CRI Report.

Market Segmentation

• Disease Type: Gastroenterology Disease, Endocrine and Metabolism Disorders Disease, Cardiovascular Disorders, Neurology Disease, Hematology and Oncology Disease, Dermatology Disease
• Product Type: Kits and Assays, Panels
• Sample Type: DNA Sample, Buccal Swab Sample, Blood, Saliva
• Technology: Next-Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays
• Trait Type: Inherited, Acquired
• Test Type: Genetic Test, General Lab Test, Imaging Test
• Age Group: Children Age, Adult Age
• End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories, Cancer Research Institutes, Universities Research Laboratories

Regional Segmentation

• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, Russia, Rest-of-Europe
• Asia-Pacific – Japan, China, India, Australia, Singapore, Rest-of-APAC
• Latin America – Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World

Growth Drivers

• Rising Prevalence of Genetic Disorders
• Increasing Research and Development in the Field of Rare Disease Diagnostics
• Rare Genome Projects Leading to Rise in Awareness Regarding Treatment of Disease
• Commitment of Big Pharma and Biotech Companies to Rare Diseases

Market Challenges

• Expensive Sequencing Procedures and Their Applications in Medical Treatments
• High Capital Requirement Hampering the Expansion of Global Reach
• Stringent Regulatory Standards

Market Opportunities

• Technological Advancements in Sample Preparation for Whole Genome and Exome Sequencing in Rare Disease Sequencing
• Huge Opportunity for Pharma and Medical Devices and Biotechnology Companies

Key Companies Profiled

23andMe Inc., 3billion, Inc., Agilent Technologies, Inc., Beijing Genomics Institute (BGI), CENTOGENE N.V., Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., In-Depth Genomics, Invitae Corporation, Laboratory Corporation of America Holdings, OPKO Health, PerkinElmer, Inc., Quest Diagnostics Incorporated, Travere Therapeutics, Inc.

Key Questions Answered in this Report:

• What are the possible long-term and short-term impacts of rare disease testing on the human health continuum?
• What are the major market drivers, challenges, and opportunities in the rare disease testing?
• What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for the global rare disease diagnostics market?
• How are service-based companies impacting the growth of the global rare disease testing industry and further shaping up future trends?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030?
• Who are the leading players with significant offerings to the global rare disease diagnostics market and what is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the unmet needs that are yet to be met by the global rare disease diagnostics market with respect to the application areas?
• What are the dynamics of various application areas and countries, which are impacting the global rare disease diagnostics market?
• What are the new market opportunities of various technologies that are influencing the growth of the global rare disease diagnostics market?
• How is each segment of the market is expected to grow during the forecast period from 2020 to 2030? Following are the segment types:
o Product
o Sample
o Technology
o Age group
o Trait
o Test
o End user
o Region

Market Overview

Rare disease diagnostics has grown significantly since the technology was first commercialized with whole genome and exome sequencing, but it is important to quantify that growth and describe future trends. The genome testing industry is proliferating, and its growth is expected to continue at a torrid pace. However, there are significant challenges that may dampen future growth, if not addressed.

Our healthcare experts have found rare disease diagnostics to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 8.57% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor diseases are acting as significant factors driving the growth of the sequencing industry. Other factors fueling the growth include increased understanding of the molecular basis of diseases, patient demand, industry investment, and regulations that allow marketing of tests without the FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that need to be addressed to facilitate future growth. The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry. Whole genome and exome sequencing remain relatively costly, requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market has been segmented on the basis of disease type, product, sample, age group, testing type, technology, end user, and region. Each of these segments cover the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of next-generation sequencing on the global level has created a buzz among companies to invest in the products and services of next-generation sequencing used for rare disease diagnostics. Due to the diverse product portfolio and intense market penetration, whole genome and exome have been pioneers in this field and significant competitors in this market.

Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

The post Global Rare Disease Diagnostics Market: Focus on Disease, Trait Type, Products, Age Group, Test Type, Technology, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030 first appeared on CRI Report.

The increasing prevalence of neurological disorders, increasing investments of biotechnology and pharmaceutical industries in R&D, and rising need for better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application, and significant investments in the development of new technologies for the treatment of epilepsy and other cardiac indications are likely to fuel the market growth during the forecast period.

According to the WHO estimates, neurological disorders are responsible for 4.5 to 11% of all the disorders in the population including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, higher cost of this treatment procedure may hamper the market growth during the corresponding period. As per the American Heart Association, currently the treatment costs for
TIA is approximately USD 20,000 which includes the cost of only one year, and it is not affordable to the patients living in low-income economies.
The global transient ischemic attack market is expected to register a CAGR of 6.08% during the forecast period, 2017–2023.

Key Players
Some of key the players in the transient ischemic attack market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Novo Nordisk A S, Becton Dickinson and Company, Medtronic PLC, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., Terumo Corporation, Ypsomed Holding AG, HTL-STREFA S.A., Sarstedt AG & Co, Owen Mumford Ltd., Greiner Bio-One, Improve Medical, Chengdu Rich Science Industry Co., Ltd., Weigao Group, Nipro, Medigard, Weihai Hongyu Medical Devices, and others.

Study Objectives
• To provide a detailed analysis of the market structure along with a forecast of the various segments and sub-segments of the global transient ischemic attack market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market, and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global transient ischemic attack market
• To provide a detailed analysis of the value chain and supply chain of the global transient ischemic attack market

Target Audience
• Medical Device Companies
• Hospitals & Clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Key Findings
• The global transient ischemic attack market is expected to reach USD 2,268.5 million by 2023 at a CAGR of 6.08%
• On the basis of diagnosis, the imaging technique segment market is expected to command the largest market share of 71.2% over the review period and is expected to grow at the fastest CAGR of 5.96% during the forecast period 2017–2023
• On the basis of treatment, the drugs segment is expected to command the largest market share of 59.2% over the review period, and the surgery segment is expected to grow at the fastest CAGR of 5.69% during the forecast period 2017–2023
• On the basis of age group, the 60+ years segment is expected to command the largest market share of 40.0% over the review period and 41-60 years is expected to register the fastest CAGR of 6.40% during the forecast period 2017–2023
• On the basis of end-user, the hospitals and clinics market is projected to reach USD 892.90 million by the end of 2023 at a CAGR of 6.31% from 2017 to 2023
• On the basis of region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. In 2016, the market was led by the Americas with 37.4% share.

The report also covers the regional analysis
• Americas
o North America
 U.S.
 Canada
o South America
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia Pacific
• The Middle East & Africa
o United Arab Emirates
o Saudi Arabia
o Oman
o Kuwait
o Qatar
o Rest of the Middle East & Africa

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Preference for Minimally Invasive Procedures
5.2.2 Rising Prevalence of Chronic Disorders
5.2.3 Improvement in Reimbursement Scenario
5.2.4 Rising Geriatric Population
5.3 Restraints
5.3.1 Rising Treatment Cost and Hospital Stay
5.3.2 Lack of Skilled Physicians
5.4 Opportunities
5.4.1 New Advancements in Catheterization Devices
5.4.2 Guide Wire Assisted Surgery in Elderly Population
5.1 Mega Trends
5.1.1 Telemedicine
5.2 Macroeconomic Indicators
5.3 Technology Trends & Assessment

6 Market Factor Analysis
6.1 Porter’s Five Forces Model
6.1.1 Threat of New Entrants
6.1.2 Bargaining Power of Suppliers
6.1.3 Threat of Substitutes
6.1.4 Bargaining Power of Buyers
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 Research &Development
6.2.2 Manufacturing
6.2.3 Distribution
6.2.4 Marketing & Sales
6.2.5 Post-Sales Monitoring
6.3 Demand & Supply: Gap Analysis
6.4 Pricing Analysis
6.5 Investment Feasibility Analysis
7 Global Transient Ischemic Attack Market, by Diagnosis
7.1 Introduction
7.2 Imaging Techniques
7.2.1 Computed Tomography (CT) scan
7.2.2 Carotid Duplex Scanning
7.2.3 Magnetic Resonance Imaging
7.2.4 Echocardiography
8 Global Transient Ischemic Attack Market, by Treatment
8.1 Introduction
8.2 Surgery
8.3 Drugs
8.3.1 Surgery
8.3.2 Drugs
8.3.2.1 Antithrombotic agents
8.3.2.2 Antiplatelets
8.3.2.3 Clopidogrel
8.3.2.4 Aspirin
8.3.2.5 Heparins
8.3.2.6 ENOXAPARIN
8.3.2.7 DALTEPARIN
8.3.2.8 Fibrinolytics
8.3.2.9 Tenecteplase
8.3.2.10 Alteplase
8.3.2.11 Antihypertensive agents
8.3.2.12 Prazosin
8.3.2.13 Moxonidine
9 Global Transient Ischemic Attack Market, by Age Groups
9.1 Introduction
9.2 0–18 years
9.3 19–40 years (Millennial)
9.4 41–60 years
9.5 60+ years
9.5.1 0-18 years
9.5.2 19-40 years
9.5.3 41-60 years
9.5.4 60+ years
10 Global Transient Ischemic Attack Market, by End-User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Diagnostic Centers
10.4 Research Laboratories
10.4.1 Hospitals
10.4.2 Diagnostic Centers
10.4.3 Research Laboratories
11 Global Transient Ischemic Attack Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America

11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 United Arab Emirates
11.5.3 Saudi Arabia
11.5.4 Rest of Middle East & Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Company Share Analysis
12.3 Recent Developments, 2013–2018
13 Company Profiles
13.1 Koninklijke Philips N.V.
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Stryker Corporation
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Johnson & Johnson Services Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Boston Scientific Corporation
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Sanofi
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Bayer AG
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Pfizer Inc.
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Siemens AG
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 F. Hoffmann-La Roche AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 GE Healthcare
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Penumbra, Inc.
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
13.12 Medtronic PLC
13.12.1 Company Overview
13.12.2 Financial Overview
13.12.3 Products Offering
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.12.6 Key Strategy
13.13 Abbott Laboratories
13.13.1 Company Overview
13.13.2 Financial Overview
13.13.3 Products Offering
13.13.4 Key Developments
13.13.5 SWOT Analysis
13.13.6 Key Strategy
13.14 Merck & Co., Inc.
13.14.1 Company Overview
13.14.2 Financial Overview
13.14.3 Products Offering
13.14.4 Key Developments
13.14.5 SWOT Analysis
13.14.6 Key Strategy
13.15 Boehringer Ingelheim GmbH
13.15.1 Company Overview
13.15.2 Financial Overview
13.15.3 Products Offering
13.15.4 Key Developments
13.15.5 SWOT Analysis
13.15.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.2 References

The post Global Transient Ischemic Attack Market Research Report: Forecast to 2023 first appeared on CRI Report.